Solid hypervascular liver lesions: Accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration

Investigative Radiology

Volumn 46, Issue 4, 2011, Pages 225-239

  Morana, Giovanni ^a   Grazioli, Luigi ^b   Kirchin, Miles A ^c   Bondioni, Maria Pia ^b   Faccioli, Niccolò ^d   Guarise, Alessandro ^a   Schneider, Günther ^e  

^a OSPEDALE CA FONCELLO   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Bracco Imaging SpA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

contrast agents; focal liver lesions; gadobenate dimeglumine (MultiHance); hepatobiliary phase MR imaging; magnetic resonance imaging

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CHILD; DIAGNOSTIC ACCURACY; FEMALE; HEPATOBILIARY RADIOGRAPHY; HUMAN; LIVER ADENOMA; LIVER ADENOMATOSIS; LIVER CELL CARCINOMA; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HISTOLOGY; LIVER METASTASIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; NODULAR REGENERATIVE HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL CHOLANGIOCARCINOMA; PORTAL VEIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

EID: 79952441292     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181feee3a     Document Type: Article

References (61)

1. Ba-Ssalamah A, Uffmann M, Saini S, et al. Clinical value of MRI liverspecific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol. 2009;19:342-357.
2. Oliva MR, Saini S. Liver cancer imaging: role of CT, MRI, US and PET. Cancer Imaging. 2004;4(spec no A):S42-S46.
3. Braga L, Guller U, Semelka RC. Modern hepatic imaging-review-. Surg Clin North Am. 2004;84:375-400. (Pubitemid 38388273)
4. Elsayes KM, Leyendecker JR, Menias CO, et al. MRI characterization of 124 CT-indeterminate focal hepatic lesions: evaluation of clinical utility. HPB (Oxford). 2007;9:208-215. (Pubitemid 46939115)
5. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material enhanced MR imaging. Radiology. 1994;190:417-423. (Pubitemid 24044245)
6. Morana G, Salviato E, Guarise A. Contrast agents for hepatic MRI. Cancer Imaging. 2007;7(spec no A):S24-S27. (Pubitemid 350143143)
7. Morana G, Grazioli L, Testoni M, et al. Contrast agents for hepatic magnetic resonance imaging. Top Magn Reson Imaging. 2002;13:117-150.
8. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd- BOPTA): an overview. Invest Radiol. 1998;33:798-809.
9. Spinazzi A, Lorusso V, Pirovano G, et al. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol. 1998;5(suppl 1): S86-S89.
10. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with Gd-BOPTA: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol. 1999;6:282-291. (Pubitemid 32673373)
11. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol. 2004;14:5-13. (Pubitemid 38181049)
12. Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol. 2005;15:220-228.
13. Petersein J, Spinazzi A, Giovagnoni A, et al. Evaluation of the efficacy of gadobenate dimeglumine in MR imaging of focal liver lesions: a multicenter phase III clinical study. Radiology. 2000;215:727-736. (Pubitemid 30346007)
14. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol. 2000;175:1111-1120.
15. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol. 2000;35:25-34. (Pubitemid 30033604)
16. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumineenhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210. (Pubitemid 351643147)
17. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphological and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-739. (Pubitemid 33101765)
18. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine- enhanced MR imaging: prospective study. Radiology. 2005;236:166-177. (Pubitemid 40853309)
19. Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumineenhanced MR imaging and multiphasic 64-section CT. Radiology. 2009;251: 85-95.
20. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrastenhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
21. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas ( or- 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010;45:96-103.
22. Namasivayam S, Salman K, Mittal PK, et al. Hypervascular hepatic focal lesions: spectrum of imaging features. Curr Probl Diagn Radiol. 2007;36: 107-123. (Pubitemid 46672791)
23. Chun Hsee L, McCall JL, Koea JB. Focal nodular hyperplasia: what are the indications for resection? HPB (Oxford). 2005;7:298-302. (Pubitemid 43878478)
24. De Carlis L, Pirotta V, Rondinara GF, et al. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg. 1997;3:160-165. (Pubitemid 27114028)
25. Herman P, Pugliese V, Machado MA, et al. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg. 2000;24:372-376. (Pubitemid 30117769)
26. Leese T, Farges O, Bismuth H. Liver cell adenomas: 12 years' surgical experience from a specialist hepato-biliary unit. Ann Surg. 1988;208:558-564. (Pubitemid 18267695)
27. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: a multiinstitutional study of appearance on T2-weighted and serial gadoliniumenhanced gradient-echo MR images. Radiology. 1994;192:401-406.
28. Hwang HS, Kim SH, Jeon TY, et al. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol. 2009;10:294-302.
29. Schneider G, Grazioli L, Saini SImaging of benign focal liver lesions. In: MRI of the Liver: Imaging Techniques, Contrast Enhancement, Differential Diagnosis. 2nd ed. Milan, Italy: Springer-Verlag Italia; 2006:89-149.
30. Grazioli L, Federle MP, Ichikawa T, et al. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology. 2000;216: 395-402. (Pubitemid 30599856)
31. Chiche L, Dao T, Salame E, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg. 2000;231:74-81. (Pubitemid 30043942)
32. Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging. 2007;7:2-9. (Pubitemid 47528076)
33. Murakami T, Nakamura H, Tsuda K, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging. 1995;5:165-170.
34. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology. 1994;190:49-52.
35. Kim YK, Kim CS, Lee YH, et al. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. Am J Roentgenol. 2004;182: 1217-1223. (Pubitemid 38525517)
36. Grazioli L, Morana G, Kirchin MA, et al. MR Imaging of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (Ferumoxides): an intra-individual comparison. J Magn Reson Imaging. 2003;17:593-602. (Pubitemid 36528676)
37. Gomaa AI, Khan SA, Leen EL, et al. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009;15:1301-1314.
38. Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet. 1991;173:426-431.
39. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla-published correction appears in Invest Radiol. 2006;41:859-. Invest Radiol. 2006;41: 213-221. (Pubitemid 44406181)
40. Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94. (Pubitemid 36125892)
41. Nural MS, Gokce E, Danaci M, et al. Focal liver lesions: whether a standard dose (0. 05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose. Eur J Radiol. 2008;66:65-74. (Pubitemid 351434515)
42. Schima W, Saini S, Petersein J, et al. MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses. J Magn Reson Imaging. 1999;10:80-83. (Pubitemid 29336642)
43. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240:389-400. (Pubitemid 44098634)
44. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. Am J Neuroradiol. 2008;29:1684-1691.
45. Rumboldt Z, Rowley HA, Steinberg F, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of the CNS at 3 Tesla. J Magn Reson Imaging. 2009;29:760-767.
46. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology. 2005;237:45-56. (Pubitemid 41346145)
47. Pediconi F, Catalano C, Padula S, et al. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine. Am J Roentgenol. 2008;191:1339-1346.
48. Bültmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrastenhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol. 2008;43:695-702.
49. Gerretsen SC, le Maire TF, Miller S, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology. 2010;255:988-1000.
50. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796. (Pubitemid 28053510)
51. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228. (Pubitemid 44406182)
52. Yrjänä SK, Vaara T, Karttunen A, et al. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol. 2008;43:267-275. (Pubitemid 351416770)
53. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. Am J Neuroradiol. 2008;29:668-673. (Pubitemid 351571544)
54. Carbonaro LA, Verardi N, Di Leo G, et al. Handling a high relaxivity contrast material for dynamic breast MR imaging using higher thresholds for the initial enhancement. Invest Radiol. 2010;45:114-120.
55. Caseiro-Alves F, Zins M, Mahfouz A-E, et al. Calcification in focal nodular hyperplasia: a new problem for differentiation from fibrolamellar hepatocellular carcinoma. Radiology. 1996;198:889-892. (Pubitemid 26066315)
56. Marin D, Brancatelli G, Federle MP, et al. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol. 2008;63:577-585.
57. Marin D, Catalano C, Rossi M, et al. Gadobenate dimeglumine-enhanced magnetic resonance imaging of primary leiomyoma of the liver. J Magn Reson Imaging. 2008;28:755-758.
58. Koike N, Cho A, Nasu K, et al. Role of diffusion-weighted magnetic resonance imaging in the differential diagnosis of focal hepatic lesions. World J Gastroenterol. 2009;15:5805-5812.
59. Sandrasegaran K, Akisik FM, Lin C, et al. The value of diffusion-weighted imaging in characterizing focal liver masses. Acad Radiol. 2009;16:1208-1214.
60. Feuerlein S, Pauls S, Juchems MS, et al. Pitfalls in abdominal diffusionweighted imaging: how predictive is restricted water diffusion for malignancy. Am J Roentgenol. 2009;193:1070-1076.
61. Miller FH, Hammond N, Siddiqi AJ, et al. Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. J Magn Reson Imaging. 2010;32:138-147.